# QTREX Quantum Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/QTREX Quantum Ltd.). ## Overview QTREX Quantum Ltd. is a U.S.-listed technology company that develops advanced additively manufactured electronics and specialized hardware for quantum computing infrastructure and other mission-critical applications. The company also maintains a medical technology portfolio that includes respiratory support and blood monitoring platforms. ## Products & services • Additively Manufactured Electronics (AME) • Shielded RF Monolithic components • Quantum connectivity hardware for dilution cryostats • Chip carrier and processor-interface designs • Defense, aerospace, missile and space electronics applications • Medical respiratory support platforms • Medical blood monitoring platforms - **Quantum hardware** (40%) — Connectivity and interface hardware for quantum computing systems and cryostats. - **Additively manufactured electronics** (25%) — Custom electronic components produced using the AME platform for specialized applications. - **Defense and mission-critical electronics** (20%) — Hardware and electronic components for defense, aerospace, missile, and space uses. - **Medical technology** (15%) — Respiratory support and blood monitoring products and related portfolio assets. - Additively Manufactured Electronics (AME) - Shielded RF Monolithic components - Quantum connectivity hardware for dilution cryostats - Chip carrier and processor-interface designs - Defense, aerospace, missile and space electronics applications - Medical respiratory support platforms - Medical blood monitoring platforms ## Customers QTREX sells to customers that need highly customized electronics rather than standard off-the-shelf components. Its recent disclosures point to government-owned industrial customers, quantum hardware buyers, and technical partners evaluating application-specific designs for cryogenic and control systems. The medical portfolio serves healthcare-related end markets through respiratory support and blood monitoring platforms. - **Quantum infrastructure customers** (primary) — Buy custom connectivity and interface hardware for dilution refrigerators, quantum processors, and control systems. - **Government-owned industrial customers** (primary) — Buy proprietary Shielded RF Monolithic components after testing and qualification. - **Defense, aerospace, and space programs** (secondary) — Buy AME-based electronics for mission-critical environments that need specialized performance. - **Medical technology customers** (secondary) — Buy respiratory support and blood monitoring platforms or related portfolio assets. - **Research and strategic partners** (emerging) — Evaluate chip carrier samples and processor-interface designs for future program adoption. - Government-owned and state-linked industrial customers - Quantum computing system developers - Customers building dilution refrigerators and cryostats - Defense and aerospace program integrators - Medical device users and healthcare channels ## Geography QTREX is a U.S.-listed company with operating and development activity centered in Israel, while selling into international markets. Recent disclosures reference customers outside its home market, including a leading international government-owned company, and the company presents its quantum hardware to industry participants in Boston and other commercial forums. - U.S.-listed company with Nasdaq trading in the United States - Core development and production activity is centered in Israel - Recent commercial activity includes an international government-owned customer - Sales and partner outreach extend to quantum industry hubs such as Boston - Business has cross-border exposure in defense, quantum, and medical markets ## Strategy QTREX is building a direct-to-customer model for proprietary, application-specific components rather than only selling platform technology. It is also using its manufacturing infrastructure to pursue quantum, defense, aerospace, and other high-specification electronics markets while selectively monetizing parts of its medical portfolio. - **Commercialize proprietary quantum components** (short-term) — Direct customer orders validate the move from development to recurring commercial supply. - **Scale the AME manufacturing platform** (medium-term) — In-house production and multi-technology manufacturing are central to customization and margin potential. - **Broaden defense and mission-critical applications** (medium-term) — These markets reward specialized engineering and can diversify demand beyond quantum computing. - **Monetize non-core medical assets** (medium-term) — Selective monetization can simplify the portfolio and free resources for higher-priority electronics programs. - Expand direct sales of custom quantum hardware components - Use in-house manufacturing to support tailored customer designs - Build a broader pipeline of tier-1 quantum and mission-critical customers - Advance AME applications across defense, aerospace, missile, and space - Monetize selected medical assets while retaining strategic platforms ## Risks QTREX depends on winning customer qualification, converting samples into purchase orders, and sustaining technical performance in niche hardware markets. It also carries going-concern and financing risk, while its cross-border operations add execution, customer concentration, and regulatory complexity. - **Going-concern and financing need** [critical] — The filed financial statements note substantial doubt about continuing as a going concern and the need to raise capital. - **Customer concentration and program dependency** [high] — Early commercialization relies on a small number of qualified customers and follow-on purchase orders. - **Qualification and adoption risk** [high] — Custom electronics require extensive testing, approval, and repeatability before larger deployment. - **Export control and defense regulatory risk** [medium] — Defense, aerospace, missile, and space applications may trigger licensing and compliance obligations. - **Medical asset monetization risk** [medium] — The company is actively working to monetize parts of the medical business, which may not occur as planned. - Customer qualification risk can delay or prevent commercialization - Revenue concentration on a few specialized programs may be volatile - Going-concern and capital-raising risk remain material - Cross-border defense and quantum sales face regulatory scrutiny - Medical portfolio monetization may be uncertain - Custom manufacturing adds execution and quality-control risk ## Accounting The key accounting issue is the valuation and integration of acquired AME operations, including preliminary purchase price allocation that can materially change reported asset values and future amortization. The company also flags going-concern uncertainty, and revenue recognition may depend on milestone-based orders, custom production timing, and customer acceptance in highly specialized contracts. - **Preliminary purchase price allocation** — Could alter goodwill, intangibles, and future amortization - **Going-concern assessment** — Affects liquidity assumptions and disclosure risk - **Custom contract revenue recognition** — Can shift reported revenue across quarters - **Fair value estimates** — May affect balance sheet carrying values and future expenses - Preliminary purchase price allocation may change asset and liability values - Going-concern disclosure reflects financing assumptions in the statements - Custom order timing can affect when revenue is recognized - Customer acceptance and qualification can shift revenue between periods - Estimates for acquired intangibles and fair values may be revised --- *Last updated: 2026-09-28T12:13:45.937380+00:00*